Hydroxychloroquine-induced Hyperpigmentation Research Articles

1064-nm Picosecond Laser Treatment for Hydroxychloroquine-Induced Hyperpigmentation of the Lower Extremities.

1064-nm Picosecond Laser Treatment for Hydroxychloroquine-Induced Hyperpigmentation of the Lower Extremities.

Hydroxychloroquine-induced hyperpigmentation in a patient with anti-synthetase syndrome

Hydroxychloroquine-induced hyperpigmentation in a patient with anti-synthetase syndrome

Hydroxychloroquine-induced Hyperpigmentation.

About 10–25% of patients with systemic lupus erythematosus (SLE) managed with antimalarials will develop cutaneous hyperpigmentation, and although the majority of such cases is attributed to chloroquine, hydroxychloroquine (HCQ) is also implicated and is likely underrecognized1. A 52-year-old Hispanic woman with SLE and endstage renal disease receiving peritoneal dialysis presented with a 3-month history of asymptomatic, progressive darkening of her bilateral upper extremities. There was no antecedent trauma or preceding skin …

Hydroxychloroquine-Induced Hyperpigmentation: A Case Report

Antimalarial agents, including chloroquine and hydroxychloroquine, have been used for the treatment of various rheumatoid diseases and skin diseases because of their anti-inflammatory and immune-modulating properties. Cutaneous adverse effects such as exacerbation of psoriasis, pruritus, and hyperpigmentation have been reported as side-effects of antimalarial drugs. In this case, we report a middle-aged man with a history of rheumatoid arthritis who was treated with non-steroidal anti-inflammatory drugs and hydroxychloroquine. He complainedof hyperpigmentation of the face after one year of initiating the hydroxychloroquine. It was discontinued and methotrexate was started. Skin biopsy was confirmed drug reaction. Aftermore than 10 years of follow up, his skin discoloration had not been improved.

Treatment of hydroxychloroquine-induced hyperpigmentation of the lower extremities with the Q-switched 755-nm alexandrite laser

Treatment of hydroxychloroquine-induced hyperpigmentation of the lower extremities with the Q-switched 755-nm alexandrite laser

Hydroxychloroquine-induced hyperpigmentation in systemic diseases: prevalence, clinical features and risk factors: a cross-sectional study of 41 cases.

Introduction Hydroxychloroquine is an antimalarial agent widely prescribed in internal medicine, rheumatology and dermatology. Its use can be complicated by various side effects including skin pigmentation. Objectives The aim of the study is to review epidemiological, clinical features and risk factors of hydroxychloroquine-induced pigmentation. Materials and methods We performed a cross-sectional study conducted over a period of 5 months. During this period, patients who had been treated with hydroxychloroquine for over 6 months, in the internal medicine department, underwent a complete dermatological examination. All patients completed a structured questionnaire to collect demographic data, dosage and treatment duration of hydroxychloroquine, other drug intake, hydroxychloroquine indication, and presence of pigmentary changes on the skin, nail, hair, and mucosa. Results A total of 41 patients (38 women and 3 men) were included in the study. The mean age was 39.2 ± 15.4 years. The hydroxychloroquine was indicated for systemic lupus erythematosus in 73.2%, dermatomyositis in 12.2%, rheumatoid arthritis in 9.8%, actinic lichen and sarcoidosis each in 2.4%. Cutaneous pigmented lesions were found in 21 cases (51%), mucous pigmentation in 5 cases (12%) and nail pigmentation in 1 case (2.5%). In 12 of 41 (29%) of the hydroxychloroquine users, we conclude a hydroxychloroquine-induced pigmentation. There were 11 women and one man with a mean age of 43 years and all of them were systemic lupus erythematosus patients. Pigmented lesions were located on the lower limbs in seven cases, the face in two cases, lips in two cases and the gum in two cases. Pigmentation appeared after a median duration of hydroxychloroquine treatment of 32 months with a median cumulative dose of 361 g. Overall, two patients reported that the appearance of pigmented lesions was preceded by the occurrence of ecchymotic areas following microtrauma. Significant association was found between hydroxychloroquine-induced pigmentation and treatment with oral anticoagulants and/or antiplatelet agents ( p = 0.03). Conclusion Our systematic examination of patients demonstrated that hydroxychloroquine-induced pigmentation is not rare. The imputability of hydroxychloroquine in the genesis of this discoloration is difficult to establish. Our study supports the hypothesis that ecchymosis, platelet antiaggregants and oral anticoagulants may be the main predisposing factors to hydroxychloroquine-induced pigmentation.

Hydroxychloroquine-induced hyperpigmentation

Hydroxychloroquine-induced hyperpigmentation

Hydroxychloroquine‐induced hyperpigmentation

The Journal of DermatologyVolume 39, Issue 10 p. 859-860 LETTERS TO THE EDITOR Hydroxychloroquine-induced hyperpigmentation Eun B. CHO, Eun B. CHO Department of Dermatology, Hallym University Sacred Heart Hospital, Anyang, KoreaSearch for more papers by this authorByung C. KIM, Byung C. KIM Department of Dermatology, Hallym University Sacred Heart Hospital, Anyang, KoreaSearch for more papers by this authorEun J. PARK, Eun J. PARK Department of Dermatology, Hallym University Sacred Heart Hospital, Anyang, KoreaSearch for more papers by this authorIn H. KWON, In H. KWON Department of Dermatology, Hallym University Sacred Heart Hospital, Anyang, KoreaSearch for more papers by this authorHee J. CHO, Hee J. CHO Department of Dermatology, Hallym University Sacred Heart Hospital, Anyang, KoreaSearch for more papers by this authorKwang H. KIM, Kwang H. KIM Department of Dermatology, Hallym University Sacred Heart Hospital, Anyang, KoreaSearch for more papers by this authorKwang J. KIM, Kwang J. KIM Department of Dermatology, Hallym University Sacred Heart Hospital, Anyang, KoreaSearch for more papers by this author Eun B. CHO, Eun B. CHO Department of Dermatology, Hallym University Sacred Heart Hospital, Anyang, KoreaSearch for more papers by this authorByung C. KIM, Byung C. KIM Department of Dermatology, Hallym University Sacred Heart Hospital, Anyang, KoreaSearch for more papers by this authorEun J. PARK, Eun J. PARK Department of Dermatology, Hallym University Sacred Heart Hospital, Anyang, KoreaSearch for more papers by this authorIn H. KWON, In H. KWON Department of Dermatology, Hallym University Sacred Heart Hospital, Anyang, KoreaSearch for more papers by this authorHee J. CHO, Hee J. CHO Department of Dermatology, Hallym University Sacred Heart Hospital, Anyang, KoreaSearch for more papers by this authorKwang H. KIM, Kwang H. KIM Department of Dermatology, Hallym University Sacred Heart Hospital, Anyang, KoreaSearch for more papers by this authorKwang J. KIM, Kwang J. KIM Department of Dermatology, Hallym University Sacred Heart Hospital, Anyang, KoreaSearch for more papers by this author First published: 01 June 2012 https://doi.org/10.1111/j.1346-8138.2012.01591.xCitations: 11 Kwang Ho Kim, M.D., Department of Dermatology, Hallym University Sacred Heart Hospital, 896 Pyeongchon-dong, Dongan-gu, Anyang, Gyeonggi-do 431-070 Korea. Email: dermakkh@yahoo.co.kr Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onFacebookTwitterLinkedInRedditWechat No abstract is available for this article.Citing Literature Volume39, Issue10October 2012Pages 859-860 RelatedInformation

Hydroxychloroquine-induced hyperpigmentation: a case report

The antimalarials are one of the most commonly prescribed drugs in medical practice, for conditions such as rheumatoid arthritis as well as malaria. They are generally well-tolerated and the possible side effects of synthetic antimalarials, though infrequent, are well known. Besides the familiar adverse reactions, a localized mucocutaneous bluish-grey to black discolouration can sometimes be seen with antimalarial drugs. The aim of this report was to draw attention to the localized mucocutaneous bluish-grey hyperpigmentation induced by hydroxychloroquine with a case presentation and a review of the literature.

Hydroxychloroquine‐induced hyperpigmentation: the staining pattern

We report two cases of hydroxychloroquine-induced hyperpigmentation presenting in a 50-year-old Caucasian female (case 1) and a 78-year-old female (case 2), both receiving 400 mg per day. Case 1 had an arthritis predominant undifferentiated connective tissue disease, which was treated with hydroxychloroquine for 4-5 years. She presented with a mottled, reticulated macular gray pigmentation involving the upper back and shoulders. Case 2 had a history of systemic lupus erythematosus and rheumatoid arthritis, treated with hydroxychloroquine for 1.5 years. She presented to the hospital for treatment of constrictive cardiomyopathy and was noted to have a blue macular pigmentation involving the right temple. The biopsies from both patients showed superficial dermal, yellow-brown, non-refractile and coarsely granular pigment deposition. A Fontana-Masson stain highlighted some of these granules, while the Perl's iron stain was negative. Rare, previous reports of hyperpigmentation indicate the presence of both melanin and hemosiderin in patients being treated with antimalarial medication. To our knowledge, this staining pattern for hydroxychloroquine has not been previously reported in the literature and supports that hydroxychloroquine, in addition to chloroquine, binds to melanin.